Supporting Information

Table of Contents

Supplementary Methods

Supplementary Tables

Table S1: Prediction of the amino acid specificity of adenylation domains.

Table S2: Primers used in this study.

Supplementary Figures

Fig. S1: Translocase MraY-catalyzed reaction.

Fig. S2: Proposed biosynthetic pathway for 2S,3S-DABA.

Fig. S3: Proposed biosynthetic pathway for 3'-deoxy-4',5'-enamino-uridine.

Fig. S4: Comparison of two putative *pac* gene clusters from *S. coeruleorubidus* and *S. roseosporus*.

Fig. S5: Inactivation of *pacO*, *pacP*, *pacQ*, and *pacU* in *S*. *coeruleorubidus*.

Fig. S6: Extracted ion chromatograms of pacidamycins extracted from wide-type *S. coeruleorubidus* culture.

Fig. S7: Extracted ion chromatograms of pacidamycins extracted from culture of $\Delta pacO$ mutant.

Fig. S8: Extracted ion chromatograms of pacidamycins extracted from culture of $\Delta pacP$ mutant.

Fig. S9: Extracted ion chromatograms of pacidamycins extracted from culture of $\Delta pacO$ mutant complemented by *pacO*.

Fig. S10: Extracted ion chromatograms of pacidamycins extracted from culture of $\Delta pacQ$ mutant.

Fig. S11: Extracted ion chromatograms of pacidamycins extracted from culture of $\Delta pacU$ mutant.

Fig. S12: SDS-PAGE analysis of the *E. coli* purified proteins.

Fig. S13: HRMS of the unlabeled and [¹³C]-labeled Ala-CO-Phe ureido dipeptide.

Fig. S14: HRMS of the unlabeled and [¹³C]-labeled Ala-CO-*m*-Tyr ureido dipeptide.

Supplementary Methods

Pacidamycin production and isolation. For each gene deletion experiment, three mutants were selected for pacidamycin production analysis after PCR verification (primers listed in table S2). Wild-type *S. coeruleorubidus* was grown side by side as controls with all of the mutants. Starter cultures in TSB medium were inoculated with spores and incubated at 30 °C, 200 rpm for 24 h. Production medium (20 mL; 20.99 g/L MOPS, 10 g/L lactose, 4.41 g/L K₂HPO₄, 2.14 g/L NH₄Cl, 0.6 g/L MgSO₄, 10 mg/L FeSO₄·2H₂O, 10 mg/L MnCl₂·4H₂O, 10 mg/L ZnSO₄·7H₂O, 10 mg/L CaCl₂, pH 7.0) was inoculated with starter culture (0.5 mL) and incubated at 30 °C, 200 rpm for 5 d. Pacidamycins were extracted from the cell-free broth (10 mL) using XAD-16 resin (5% v/v). The resin was washed with water (20 mL) and the extract was eluted with methanol (5 mL). The solvent was removed by a rotary evaporator and the residue was redissolved in water/methanol 1:1 (500 µL) and subjected to LC-HRMS analysis (25 µL injection).

Cloning, overexpression and purification of NRPSs. pacH, J, L, N, O, P, U were PCR amplified from genomic DNA extracted from S. coeruleorubidus (primers listed in table S2). Purified PCR products were ligated to pET-30 Xa/LIC (Novagen) following the standard protocol and confirmed by DNA sequencing. The resulting expression constructs were transformed into E. coli BL21 or BAP1 cells for protein expression. Expression and purification for all proteins followed the same general procedure and is detailed as follows. In 1 L of liquid culture, the cells were grown at 37 °C in LB medium with 50 µg/mL kanamycin to an OD600 of 0.4. The cells were cooled on ice for 10 min and then induced with 0.1 mM isopropyl- β -Dthiogalactopyranoside (IPTG) for 16 h at 16 °C. The cells were harvested by centrifugation (6000 rpm, 6 min, 4 °C), resuspended in 30 mL lysis buffer (50 mM Tris-HCl pH 8.0, 0.5 M NaCl, 5 mM imidazole) and lysed by sonication on ice. Cellular debris was removed by ultracentrifugation (35000 rpm, 30 min, 4 °C). Ni-NTA agarose resin was added to the supernatant (1 mL/L of culture) and the solution was nutated at 4 °C for 1 h. The protein resin mixture was loaded into a gravity flow column, and proteins were eluted with increasing concentrations of imidazole in Buffer A (50 mM Tris-HCl, pH 8.0, 2 mM EDTA). Purified proteins were concentrated and buffer exchanged into Buffer A + 10% glycerol using Amicon Ultra filters. The final proteins were flash-frozen in liquid nitrogen and stored at -80 °C. The approximate protein yields were 16 mg/L for PacH (10 kDa), 6 mg/L for PacJ (8 kDa), 5 mg/L for PacL (90 kDa), 16 mg/L for PacN (63 kDa), 42 mg/L for PacO (57 kDa), 17 mg/L for PacP (90 kDa), and 3 mg/L for PacU (55 kDa).

Supplementary Tables

Table S1. Prediction of the amino acid specificity of adenylation domains in pacidamycin cluster.

Protein	10 AA code	Predicted specificity
PacL	DPGIYGQLAK	Val/Leu
PacO	DLSSVGVCYK	Ala
PacP	DIWQGTADDK	Ser/Arg
PacU	DCHYFALITK	Pro/p-hydroxyphenylglycine

Primer	Sequence	Note
M119_F	5'- AGACCCTCGTGCTCGTCACG-3'	Used for $\Delta pacO$
M119_R	5'- GGACCAACTGGAGTGGCAGC-3'	mutant construction;
M119-apra_F	5'-GCGTCGAGCCATCCTGAAACTCTGAGAGGCAAACCTATGAT	M119_R is also used
	TCCGGGGATCCGTCGACC-3'	for $\Delta pacO$ mutant
M119-apra_R	5'-GTACCTGTATACGCGCCATCCTGAACGACAGATGAATTATG	verification
	TAGGCTGGAGCTGCTTC-3'	
M120_F	5'-ACAAACGCTGAGCTACCGCG-3'	Used for $\Delta pacP$
M120_R	5'- ACATTGCGGTGCTCGAACGC-3'	mutant construction
M120-apra_F	5'-AGGCCGCCACTACGTTCGGCCGGAAAGGCTGGCACTGTGAT	
N(100 D		
M120-apra_K		
M121 E		Used for AngeO
M121_F	5-AAAAAATCTAGAGCTGCTGGCCGCGGGAGAACG-3	mutant construction
MI2I_K	5'-AAAAAAGAATTCGTCCAGTGAGGCCGGGAAGG-3'	indiant construction
M121-apra_F	5'-AACGGCCATCGCGGCCACCCAGGAAGGCGGCACCCGGTGA	
M101 anna D		
MIZI-apra_K	5-0010001000000100100A0010000010010A10	
M125 F	$\frac{1}{2} C C A C A T C C A C C A C C T C C T A 2'$	Used for ApacU
M125_P		mutant construction
M125_K		
M125-apra_F		
M125 opro D		
WI125-apra_K	AGGCTGGAGCTGCTTC_3'	
Apra i	5'-AGTTGTCTCTGACACATTCT_3'	Internal primer for
		mutants verification
121_PET30R	5'-AGAGGAGAGTTAGAGCCTTATACGACTCCCCCGGCCGTG-3'	External primer for
		$\Delta pacP$ mutant
		verification
122_PET30R	5'-AGAGGAGAGTTAGAGCCTTATTGAAGATCATTACTTGGT-3'	External primer for
		$\Delta pacQ$ mutant
10(DET20D		verification
126_PE130R	5'-AGAGGAGAGTTAGAGCCTTAGGCCTGGGGAGCGCCGTT-3'	External primer for
		$\Delta paco$ mutant
119c Ndel		Used for <i>pacO</i>
119c EcoRI	5'- AAAAAAGAATTCTTAGGGGCGCCGAGTTCGGC-3'	complementation
111a PET30F	5'-GGTATTGAGGGTCGCATGAATCTACAGGATCAGAA-3'	Used for PacH
111a PET30R	5'-AGAGGAGAGTTAGAGCCTTATTTCCTGGTGCCGTTCGCA-3'	expression
113 NdeI	5'-AAAAAACATATGTTCGACGACGAGGGGGCG-3'	Used for PacJ
113 EcoRI	5'-AAAAAAGAATTCGGGGCGGCTGATCCCTCATCGG-3'	expression
115_PET30F	5'-GGTATTGAGGGTCGCATGTCGACCACAGATGACGC-3'	Used for PacL
115_PET30R	5'-AGAGGAGAGTTAGAGCCTTAGAGCATCGCCGCGAGCTCA-3'	expression
117_PET30F	5'-GGTATTGAGGGTCGCATGTTCCCGCTGAGCGCCTCA-3'	Used for PacN
117_PET30R	5'-AGAGGAGAGTTAGAGCCTTAACGCTGGAGGTCGGGGGGTC-3'	expression
119_PET30F	5'-GGTATTGAGGGTCGCATGCGCGATGCAGTAGCCGC-3'	Used for PacO
119_PET30R	5'-AGAGGAGAGTTAGAGCCTTAGGGGCGCCGAGTTCGGC-3'	expression, pacO
		complementation
115 PET30R 117 PET30F 117 PET30R 119 PET30F 119 PET30R	5'-AGAGGAGAGTTAGAGCCTTAGAGCATCGCCGCGAGCTCA-3' 5'-GGTATTGAGGGTCGCATGTTCCCGCTGAGCGCCTCA-3' 5'-AGAGGAGAGTTAGAGCCTTAACGCTGGAGGTCGGGGGGTC-3' 5'-GGTATTGAGGGTCGCATGCGCGATGCAGTAGCCGC-3' 5'-AGAGGAGAGTTAGAGCCTTAGGGGCGCCGAGTTCGGC-3'	expression Used for PacN expression Used for PacO expression, <i>pacO</i> complementation verification

120_PET30F	5'-GGTATTGAGGGTCGCATGACGGAGCAGGTCGAGGCA-3'	Used for PacP
120_PET30R	5'-AGAGGAGAGTTAGAGCCTTACCGGGTGCCGCCTTCCTGG-3'	expression
125D_PET30F	5'-GGTATTGAGGGTCGCATGTCTCTCACATTGGTCGA-3'	Used for PacU
125_PET30R	5'-AGAGGAGAGTTAGAGCCTTAACCGGCCAACCCCGCCGCC-3'	expression

Supplementary Figures



Fig. S1. Translocase MraY-catalyzed reaction: UDPMurNAc-pentapeptide is cleaved to release UMP, and phospho-*N*-acetylmuramoyl-pentapeptide motif is transferred onto undecaprenyl phosphate carrier lipid to form lipid intermediate I during bacterial cell wall assembly.



Fig. S2. Proposed biosynthetic pathway for 2S,3S-DABA.



Fig. S3. Proposed biosynthetic pathway for 3'-deoxy-4',5'-enamino-uridine.



Fig. S4. Comparison of two putative *pac* gene clusters from *S. coeruleorubidus* and *S. roseosporus*. All *pac* genes identified from *S. coeruleorubidus* are present in *S. roseosporus*. Three additional genes are found in the cluster of *S. roseosporus*, one encoding a phenylalanine hydroxylase homolog and the other two encoding hypothetical proteins.



Fig. S5. Inactivation of *pacO*, *pacP*, *pacQ*, and *pacU* in *S. coeruleorubidus*. All genes were deleted in-frame by homologous recombination as illustrated above. The genomic DNA of wide-type and mutant strains was extracted and used as templates for subsequent PCR verification of mutants. PCR was carried out using one internal primer from acc(3)IV-oriT cassette and one external primer from an adjacent gene (Table S2). The size of PCR product was consistent with the expected size of each mutant.



Fig. S6. Extracted ion chromatograms of pacidamycins extracted from wide-type *S*. *coeruleorubidus* culture.



Fig. S7. Extracted ion chromatograms of pacidamycins extracted from culture of $\Delta pacO$ mutant. The change in the y-axis of the mass signal scale (compared to Fig. S6) led to the appearance of mass noise.



Fig. S8. Extracted ion chromatograms of pacidamycins extracted from culture of $\Delta pacP$ mutant. The change in the y-axis of the mass signal scale (compared to Fig. S6) led to the appearance of mass noise.



Fig. S9. Extracted ion chromatograms of pacidamycins extracted from culture of $\Delta pacO$ mutant complemented by *pacO*.



Fig. S10. Extracted ion chromatograms of pacidamycins extracted from culture of $\Delta pacQ$ mutant. The change in the y-axis of the mass signal scale (compared to Fig. S6) led to the appearance of mass noise.



Fig. S11. Extracted ion chromatograms of pacidamycins extracted from culture of $\Delta pacU$ mutant.



Fig. S12. SDS-PAGE analysis of the *E. coli* purified proteins. Most proteins have *N*-terminal hexahistidine tag except that PacJ has a *C*-terminal hexahistidine tag.



Fig. S13. HRMS of the unlabeled and [¹³C]-labeled Ala-CO-Phe ureido dipeptide.



Fig. S14. HRMS of the unlabeled and $[^{13}C]$ -labeled Ala-CO-*m*-Tyr ureido dipeptide.